Should ocrelizumab be used in non-active primary progressive multiple sclerosis? Time for a re-assessment

Navid Manouchehri, Olaf Stüve

Research output: Contribution to journalLetterpeer-review

Original languageEnglish (US)
JournalTherapeutic Advances in Neurological Disorders
Volume14
DOIs
StatePublished - 2021

ASJC Scopus subject areas

  • Pharmacology
  • Neurology
  • Clinical Neurology

Cite this